The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of radionuclide-based high-dose-rate brachytherapy. Brachytherapy 2017;16(1):75-84
Date
01/23/2017Pubmed ID
28109634DOI
10.1016/j.brachy.2016.05.006Scopus ID
2-s2.0-85009876022 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
Brachytherapy is a radiation therapy method in which radionuclide sources are used to deliver a radiation dose at a distance of up to a few centimeters by surface, intracavitary, intraluminal, or interstitial application. This practice parameter refers only to the use of radionuclides for brachytherapy. Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer. High-dose-rate (HDR) brachytherapy uses radionuclides such as iridium-192 at dose rates of 20 cGy per minute (12 Gy per hour) or more to a designated target point or volume. High-dose-rate (HDR) brachytherapy is indicated for treating malignant or benign tumors where the treatment volume or targeted points are defined and accessible.
Author List
Erickson BA, Bittner NH, Chadha M, Mourtada F, Demanes DJAuthor
Beth A. Erickson MD Professor in the Radiation Oncology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
BrachytherapyHealth Personnel
Humans
Iridium Radioisotopes
Neoplasms
Patient Selection
Radiation Oncology
Radioisotopes
Radiology
Radiotherapy Dosage
Societies, Medical
United States